Redeye updates on Better Collective ahead of Q4-results (due February 19) where we expect a slight s...
Redeye is encouraged to see organic growth in the quarter after a relatively weak performance during...
Redeye continues to see a compelling long-term investment case.
Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell the...
Q4 with meagre 5% organic growth and EBITDA 2% below But quite a few positives in the underlying ope...
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.
Hyresintäkterna steg med 38% till 12,4 meur och förvaltningsresultat ökade med 37% till 6,2 meur på ...
NOI +41% y-o-y and +1% vs ABGSCe Value uplift -0.3% q-o-q, net LTV at 52.
Endomines releases its H2/24 results on 13th of February.
F&MT initiates cost-cutting program Gradual recovery expected Q4 due on 10 February Q4e: Organic sa...
On February 4thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has agreed to sell I...
Redeye shares its initial thoughts on CTEK’s Q4 report.
Redeye provides its initial take on Vitec’s Q4 2024 report, which featured sales that clearly exceed...
Redeye comments on the Q4 report released earlier this morning.
Redeye returns with a more in-depth take on OssDsign’s Q4 report.
Navamedic ASA (”Navamedic” or ”the Company”) is a Nordic pharmaceutical company offering a diversifi...
Q4 a tad soft at 5% organic growth and EBIT -6% But the undelrying business appears in very good sha...
Sales and gross margin above expectations in Q4 EBIT revised up by 2.
Kingspan bids SEK 182.5/shareNWG's board recommends accepting the bidHighly likely the bid will go t...
Redeye provides initial comments on Sleep Cycle’s Q4 report, in which sales were in line with expect...